RSV-specific binding molecule

Patent metadata

Field	Value
Publication number	US-10723786-B2
Application number	US-201816047524-A
Country	US
Kind code	B2
Filing date	Jul 27, 2018
Priority date	Oct 6, 2009
Publication date	Jul 28, 2020
Grant date	Jul 28, 2020

Abstract

The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.

First claim

The invention claimed is:

1. An antibody, or functional part thereof,
wherein the antibody or functional part thereof specifically binds to a Respiratory Syncytial Virus (RSV) F protein, comprises a heavy chain CDR1 sequence comprising the sequence KLSIH (SEQ ID NO:4), a heavy chain CDR2 sequence comprising the sequence GYEGEVDEIFYAQKFQH (SEQ ID NO:8), a heavy chain CDR3 sequence comprising the sequence LGVTVTEAGLGIDDY (SEQ ID NO:12), a light chain CDR1 sequence comprising the sequence RASQIVSRNHLA (SEQ ID NO:20), a light chain CDR2 sequence comprising the sequence GASSRAT (SEQ ID NO:24), and a light chain CDR3 sequence comprising the sequence LSSDSSI (SEQ ID NO:28), and
wherein the antibody, or functional part thereof, comprises a Fc region comprising a modification at one or more positions selected from the group consisting of 234, 235, 236, 237, 238, 239, 240, 241, 243, 244, 245, 247, 251, 252, 254, 255, 256, 262, 263, 264, 265, 266, 267, 268, 269, 279, 280, 284, 292, 296, 297, 298, 299, 305, 313, 316, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 339, 341, 343, 370, 373, 378, 392, 416, 419, 421, 440 and 443 as numbered by the EU index of Kabat, said modification comprising an amino acid substitution, and/or an amino acid insertion, and/or an amino acid deletion.

2. The antibody or functional part thereof of claim 1 , wherein the antibody or functional part thereof comprises a human IgG1 heavy chain.

3. The antibody or functional part thereof of claim 2 , wherein the Fc region modification comprises amino acid substitutions at amino acid positions 252, 254, and/or 256.

4. The antibody or functional part thereof of claim 3 , wherein the amino acid substitution at amino acid position 252 is a substitution with tyrosine, the amino acid substitution at amino acid position 254 is a substitution with threonine, and/or the amino acid substitution at amino acid position 256 is a substitution with glutamic acid.

5. The antibody or functional part thereof of claim 3 , wherein the amino acid substitution at amino acid position 252 is a substitution with tyrosine, the amino acid substitution at amino acid position 254 is a substitution with threonine, and the amino acid substitution at amino acid position 256 is a substitution with glutamic acid.

6. A pharmaceutical composition comprising the antibody or functional part thereof of claim 1 .

7. A pharmaceutical composition comprising the antibody or functional part thereof of claim 3 .

8. A pharmaceutical composition comprising the antibody or functional part thereof of claim 5 .

9. A method for treating and/or preventing a RSV-related disorder, the method comprising administering to an individual in need thereof a therapeutically effective amount of the antibody or functional part thereof of claim 3 .

10. A method for treating and/or preventing a RSV-related disorder, the method comprising administering to an individual in need thereof a therapeutically effective amount of the antibody or functional part thereof of claim 5 .

11. A pharmaceutical composition comprising an isolated antibody or functional part thereof of claim 1 and at least one other isolated RSV-specific antibody or functional part thereof.

12. The pharmaceutical composition of claim 11 wherein the at least one other isolated RSV-specific antibody or functional part thereof specifically binds to the RSV F protein and comprises:
a heavy chain comprising the CDR1, CDR2, and CDR3 sequences of palivizumab and a light chain comprising the CDR1, CDR2, and CDR3 sequences of palivizumab; or
a heavy chain comprising the CDR1, CDR2, and CDR3 sequences of D25 and a light chain comprising the CDR1, CDR2, and CDR3 sequences of D25; or
a heavy chain comprising the CDR1, CDR2, and CDR3 sequences of AM14 and a light chain comprising the CDR1, CDR2, and CDR3 sequences of AM14; or
a heavy chain comprising the CDR1, CDR2, and CDR3 sequences of AM16 and a light chain comprising the CDR1, CDR2, and CDR3 sequences of AM16; or
a heavy chain comprising the CDR1, CDR2, and CDR3 sequences of AM23 and a light chain comprising the CDR1, CDR2, and CDR3 sequences of AM23.

13. A method for treating and/or preventing a RSV-related disorder, the method comprising administering to an individual in need thereof a therapeutically effective amount of the antibody or functional part thereof of claim 2 .

14. A method for treating and/or preventing a RSV-related disorder, the method comprising administering to an individual in need thereof a therapeutically effective amount of the antibody or functional part thereof of claim 4 .

15. A method for treating and/or preventing a RSV-related disorder, the method comprising administering to an individual in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 6 .

16. A method for treating and/or preventing a RSV-related disorder, the method comprising administering to an individual in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 7 .

17. A method for treating and/or preventing a RSV-related disorder, the method comprising administering to an individual in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 8 .

18. A method for treating and/or preventing a RSV-related disorder, the method comprising administering to an individual in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 11 .

19. A method for treating and/or preventing a RSV-related disorder, the method comprising administering to an individual in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 12 .

Assignees

• Medimmune Ltd

Inventors

• Beaumont Tim
• Bakker Adrianus Q
• Yasuda Etsuko

Classifications

• C07K16/11 Primary

  Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV] · CPC title

• A61P31/14

  for RNA viruses · CPC title

• C07K2317/52

  Constant or Fc region; Isotype · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title